Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Emicizumab by Chugai Pharmaceutical for Acquired Hemophilia A: Likelihood of Approval
Emicizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Acquired Hemophilia A. According to GlobalData,...
Emicizumab by Chugai Pharmaceutical for Von Willebrand Disease (vWD): Likelihood of Approval
Emicizumab is under clinical development by Chugai Pharmaceutical and currently in Phase I for Von Willebrand Disease (vWD). According to...
Emicizumab by Chugai Pharmaceutical for Acquired Hemophilia A: Likelihood of Approval
Emicizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Acquired Hemophilia A. According to GlobalData,...